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Abstract
Introduction: Cytosine residues in CpG dinucleotides often undergo various types of modification, such as
methylation, deamination, and halogenation. These types of modifications can be pro-mutagenic and can
contribute to the formation of mutational hotspots in cells. To analyze mutations induced by DNA modifications
in the human genome, we recently developed a system for tracing DNA adducts in targeted mutagenesis
(TATAM). In this system, a modified/damaged base is site-specifically introduced into intron 4 of thymidine kinase
genes in human lymphoblastoid cells. To further the understanding of the mutagenesis of cytosine modification,
we directly introduced different types of altered cytosine residues into the genome and investigated their
genomic consequences using the TATAM system.
Findings: In the genome, the pairing of thymine and 5-bromouracil with guanine, resulting from the deamination of
5-methylcytosine and 5-bromocytosine, respectively, was highly pro-mutagenic compared with the pairing of uracil
with guanine, resulting from the deamination of cytosine residues.
Conclusions: The deamination of 5-methylcytosine and 5-bromocytosine rather than that of normal cytosine
dramatically enhances the mutagenic potential in the human genome.
Keywords: Mutagenesis, Gene targeting, Deamination, Mutagenic potential
Introduction
CpG dinucleotides in the genome are subjected to vari-
ous types of modification including cytosine methyla-
tion. The methylation of cytosine to 5-methylcytosine
(5-mC) is a common DNA modification and is import-
ant for the epigenetic mechanism of gene regulation in
higher eukaryotes. In mammalian cells, 3–6 % of cyto-
sine residues and 70–80 % of cytosine residues in CpG
dinucleotides are methylated [1–3]. Such cytosine resi-
dues often undergo inappropriate modifications (Fig. 1a),
leading to genomic instability.
Cytosine and 5-mC in the genome are often spontan-
eously deaminated to form U:G and T:G mismatches, re-
spectively [4]. These mismatches are also produced by
enzymatic deamination caused by activation-induced
deaminase or apolipoprotein B mRNA editing enzyme,
catalytic polypeptide-like 3A (APOBEC3A) [5–7]. The
resultant uracil and thymine can pair with adenine during
DNA replication, causing C:G to T:A transition mutations.
In fact, cytosine residues at CpG dinucleotides in the
tumor suppressor gene TP53 is known as a mutational
hotspot in carcinoma cells [8]. It has been suggested that
in DNA, the hydrolytic deamination of 5-mC occurs more
rapidly than that of cytosine [9, 10].
Cytosine modification also occurs during chronic in-
flammation. At inflammation sites, phagocytic cells gen-
erate peroxidases that produce reactive oxidants such as
hypobromous acid and hypochlorous acid [11–13]. These
oxidants can result in several types of halogenated DNA
damages, leading to mutagenesis [14–20]. Among them,
the halogenation of cytosine is detrimental to organisms.
For example, 5-bromocytosine (5-BrC) and 5-chlorocytosine
(5-ClC) in DNA can potentially compromise epigenetic sig-
nals by mimicking 5-mC [21]. Moreover, 5-BrC is converted
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to 5-bromouracil (5-BrU) by APOBEC3A [22], which may
result in enhanced mutagenesis in the genome.
The mutagenesis of modified/deaminated cytosine resi-
dues has been extensively studied in Escherichia coli and in
plasmids introduced into mammalian cells [4, 10, 23–27].
However, the mutagenic consequences of such alterations
in the human genome are yet to be completely understood.
We recently developed a system for tracing DNA adducts
in targeted mutagenesis (TATAM) by directly introducing a
DNA modification site specifically into intron 4 of the
A
B
Fig. 1 Overview of the TATAM system. Structures of cytosine alteration (a) and the principle of the TATAM system (b). X on the targeting vector
indicates the position of cytosine, 5-mC, 5-BrC, U, 5-BrU, or thymine at the BssSI site. The targeting vectors pvINTC:G, pvINT5mC:G, pvINT5BrC:G,
pvINTU:G, pvINT5BrU:G, or pvINTT:G and the I-SceI expression plasmid pCBASce were co-transfected into TSCER122 cells. Double-strand break at
the I-SceI site enabled gene targeting by inducing site-specific homologous recombination. The targeting vector contained an MseIR site that
was resistant to MseI digestion and thereby distinguished targeted and non-targeted revertants of TK. TK revertants were selected by using HAT.
Genomic DNA of the revertant colonies was prepared, and part of the TK gene containing the modified DNA integrated site was amplified by PCR.
The amplified fragment was sequenced as described in the Materials and Methods section
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thymidine kinase (TK) gene in human lymphoblastoid cells
(Fig. 1b) [28]. In this study, for better understanding the
mutagenesis of cytosine modification in vivo, we introduced
cytosine, 5-mC, and 5-BrC paired with guanine and their
deamination products U:G, T:G, and 5-BrU:G mismatch




The human lymphoblastoid TSCER122 cells used were
derivatives of TK6 cells, as reported previously [28].
Cells were maintained in RPMI 1640 medium (Nacalai
Tesque) supplemented with 10 % horse serum (JRH Bio-
sciences), 200 μg/ml of sodium pyruvate, 100 U/ml of
penicillin, and 100 μg/ml of streptomycin at 37 °C under
5 % CO2 and 100 % humidity.
Outline of the TATAM system
TSCER122 cells are compound heterozygous for the TK
gene (TK −/−) because of the complete loss of exon 5 in
one allele and a point mutation in exon 4 in the other
(Fig. 1b). Because there is an I-SceI recognition site in
the original exon 5 region, the expression of the I-SceI
enzyme in TSCER122 cells generated a double-strand
break in the TK gene, allowing for the generation of the
wild type TK (TK +/−) by homologous recombination
with the targeting vector. TSCER122 cells were co-
transfected with the I-SceI expression plasmid and the
targeting vector site-specifically containing a synthetic
DNA adduct. After 3 days incubation, cells were seeded
96-well plates in the presence of hypoxanthine, aminop-
terin, and thymidine (HAT) to isolate the DNA adduct-
integrated revertant clones. Subsequently, the TK gene
loci of the revertant clones were sequenced (Fig. 1b).
Preparation of site-specific modified targeting vector
The targeting vectors pvINTC:G, pvINT5mC:G, pvINT5BrC:G,
pvINTU:G, pvINT5BrU:G, and pvINTT:G containing C:G,
5-mC:G, 5-BrC:G, U:G, 5-BrU:G, and T:G base pairs,
respectively, in place of the underlined cytosine/guanine at
the BssSI site (5′–CTCGTG/5′–CACGAG) were prepared
by a polymerase chain reaction (PCR)-based method
with the plasmid pTK15, as previously described (Fig. 2)
[28, 29]. A 5′–TTCA sequence (MseIR) was labeled
near the modified BssSI site. This modified site was re-
sistant to MseI digestion and thus distinguished tar-
geted and non-targeted revertants of TK according to
an interallelic recombination (Fig. 1b). The vectors were
sequenced to confirm the presence of the modified cyto-
sine at the expected site.
Transfection and cloning of TK revertant cells
DNA transfection was performed as previously described
[28]. Briefly, the targeting vector (1 μg) and I-SceI ex-
pression plasmid pCBASce (50 μg) were co-transfected
into 5 × 106 cells that were suspended in 0.1 ml of
Nucleofector Solution V (Lonza) using Nucleofector I,
in accordance with the manufacturer’s instructions. After
incubation for 72 h, cells were seeded into 96-microwell
plates in the presence of HAT (200 μM hypoxanthine,
0.1 μM aminopterin, and 17.5 μM thymidine) for isolating
targeting vector-integrated revertant clones. After incuba-
tion for 2 weeks, drug-resistant colonies (TK revertants)
were analyzed.
Mutation analysis
Genomic DNA templates for PCR were prepared from
TK-revertant colonies using alkaline lysis, as previously
described [30]. Briefly, cells were treated with 18 μl of
50 mM NaOH at 95 °C for 10 min and neutralized by
adding 2 μl of 1 M Tris-HCl (pH 8.0). The cell lysates
were then used as templates for PCR to amplify the
TK gene fragments containing the modified cytosine
integration site. PCR was performed using KOD FX
(Toyobo) with the following primers: forward primer
5′–GCT CTT ACG GAA AAG GAA ACA GG–3′ and
reverse primer 5′–CTG ATT CAC AAG CAC TGA AG–
3′. The resulting DNA fragments were sequenced using
an ABI 3730×l DNA analyzer (Applied Biosystems), and
clones harboring the MseIR sequence were counted for de-
termining the frequency of modified cytosine integration
and numbers of mutations at the BssSI site. The integra-
tion frequency of the modified cytosine was calculated by
Fig. 2 Details of the site of modification. The position of a modification is indicated by X in the primer sequence. An unmodified cytosine, 5-mC,
5-BrC, U, 5-BrU, or thymine paired with guanine was inserted at the BssSI site. The MseIR site was placed near the BssSI site
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dividing the number of MseIR clones by the total number
of revertant clones analyzed. A single point mutation was
defined as a single base substitution, insertion, or deletion
detected at the modified cytosine. Multiple mutations
were multiple base substitutions, deletions, and/or inser-
tions that were detected at sites including the modified
cytosine. Base substitutions, deletions, and/or insertions
found at sites other than the modified cytosine were de-
fined as non-targeted. Mutant proportions were calculated
by dividing the number of mutants by the number of
MseIR-bearing clones.
Statistical analysis
Statistical significance was evaluated by Fisher’s exact
test. P-values less than 0.01 were considered to be statis-
tically significant.
Results and discussion
To investigate the mutagenic potential of cytosine alter-
ations in the genome, targeting vectors pvINTC:G,
pvINT5mC:G, pvINT5BrC:G, pvINTU:G, pvINT5BrU:G, and
pvINTT:G were prepared, containing C:G, 5-mC:G, 5-
BrC:G, U:G, 5-BrU:G, and T:G base pairs, respectively,
as previously reported [28]. The revertant frequencies
were comparable between the targeting vectors used
(data not shown), indicating that the modified residues
on the targeting vector did not influence the efficiency
of homologous recombination.
Mutagenic potential of 5-methylcytosine and
5-bromocytosine in the genome
As shown in Table 1, the total proportion of mutants in-
duced by the integration of pvINTC:G, the control vector,
was 1.5 %; no C:G to T:A transition mutations were ob-
served (Fig. 3). When pvINT5mC:G was integrated, the
proportion of mutants (1.4 %) was comparable to that of
pvINTC:G. Some C:G to T:A transition mutations (0.44 %)
were detected, followed by one base deletion (0.20 %), one
base insertion (0.20 %), and non-targeted mutations, re-
ferred to as “others” (0.59 %), indicating that 5-mC itself
enhances C:G to T:A transition mutations via its deamin-
ation, but the frequency is below that of background
mutations in this system. This is in agreement with the











Single point mutationb Multiplee Othersf Total
mutation
NDg
T G A Delc Insd
pvINTC:G 457 410 (100 %) 403 (98 %) 0 0 0 2 (0.49 %) 1 (0.24 %) 0 3 (0.73 %) 6 (1.5 %) 1
pvINT5mC:G 722 676 (100 %) 667 (99 %) 3 (0.44 %) 0 0 1 (0.20 %) 1 (0.20 %) 0 4 (0.59 %) 9 (1.4 %) 0
pvINT5BrC:G 778 705 (100 %) 700 (99 %) 0 2 (0.28 %) 0 0 0 0 3 (0.43 %) 5 (0.71 %) 3
pvINTU:G 369 335 (100 %) 309 (92 %) 16 (4.8 %) 2 (0.60 %) 0 1 (0.30 %) 2 (0.60 %) 0 3 (0.90 %) 34 (8.1 %) 2
pvINTT:G 187 176 (100 %) 77 (44 %) 98 (56 %)h 0 0 0 0 0 0 98 (56 %) 1
pvINT5BrU:G 619 524 (100 %) 349 (67 %) 167 (32 %)h 4 (0.76 %) 0 1 (0.19 %) 0 2 (0.38 %) 1 (0.19 %) 175 (33 %) 2
aX:G indicates C:G, 5-mC:G, 5-BrC:G, U:G, T:G, 5-BrU:G mispair
bA single base substitution, one-base insertion, or one-base deletion detected at the modified base
cOne-base deletion
dOne-base insertion
eMultiple base substitutions, deletions, and/or insertions detected at sites including the modified base in the BssSI site
fMutations found at sites other than the modified base
gNot detectable
hP < 0.01 (significant difference versus pvINTU:G)
Fig. 3 Proportions of C:G to T:A transition mutations induced by the
integration of the targeting vector. Proportions of C:G to T:A transition
mutations induced by the integration of pvINTC:G, pvINT5mC:G, pvINT5BrC:G,
pvINTU:G, pvINT5BrU:G, and pvINTT:G in TSCER122 cells. Data are
derived from at least two independent transfections. The results
are also tabulated in Table 1
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finding that the frequency of mutations induced by 5-mC
ranges from 10−3 to 10−7 in E. coli with different genetic
backgrounds [10, 22, 31].
Regarding halogenated cytosine, it has been suggested
that 5-ClC causes C:G to T:A transition mutations at
rates ranging from 5 to 9 % by mispairing with adenine
in E. coli [32]. Based on our results, however, 5-BrC did
not induce C:G to T:A transition mutations (0 %, Fig. 3
and Table 1). The total proportion of mutants induced
by pvINT5BrC:G (0.71 %) was comparable to that of the
control vector. This low pro-mutagenicity of 5-BrC is
consistent with an in vitro analysis demonstrating that
human DNA polymerases bypass 5-BrC without detect-
able miscoding [19]. The inconsistency between the previ-
ous study on 5-ClC and our results for 5-BrC is probably
due to the different atomic radii of the halogens, effects of
the specific DNA sequence context, or distinct repair
mechanisms between E. coli and human cells.
Mutagenic potential of U:G and 5-BrU:G mismatch in the
genome
The integration of pvINTU:G mainly induced C:G to T:A
transition mutations (4.8 %), and the total proportion of
mutants was 8.1 % (Fig. 3 and Table 1). This mutagenesis
caused by the U:G mismatch in the genome is consistent
with that in previous reports describing the well-known
pro-mutagenicity of the uracil residue [4, 33]. Furthermore,
the proportion of mutants was dramatically enhanced
when pvINT5BrU:G was integrated (33 %), resulting in an
approximately 7-fold higher proportion of C:G to T:A tran-
sition mutations than that occurring when pvINTU:G was
integrated (4.8 %) (Fisher’s exact test, P < 0.01). This indi-
cates that a bromine atom at the 5′–position of uracil inter-
feres with repair using enzymes such as DNA glycosylases
in the genome, thereby resulting in enhanced mutagenesis.
Mutagenic potential of T:G mismatch in the genome
Unexpectedly, the integration of the T:G mismatch
(pvINTT:G) accounted for the highest proportion of mu-
tants (56 %) (Table 1). Notably, all these mutants harbored
C:G to T:A transition mutations, and the proportion of
such mutations was 12-fold higher than that associated
with the integration of a U:G mismatch (4.8 %) (Fisher’s
exact test, P < 0.01) (Fig. 3). This high pro-mutagenicity of
T:G mispairing is in contrasts with a previous report de-
scribing that T:G mismatches in episomal DNA are prefer-
entially repaired to C:G at an approximate efficiency of
90 % by mismatch repair in mammalian cells [27]. Al-
though our cell lines are mismatch repair proficient [34],
the integrated T:G mismatch in the TK locus did not seem
to have been corrected. Therefore, the repair efficiency of
the T:G mismatch by the specific mismatch repair might
depend on the genomic loci where the mismatch has been
integrated. Our in vivo results are in agreement with those
in a previous in vitro study demonstrating that the repair
of mismatched T:G is far less efficient than that of mis-
matched U:G at a mutational hotspot sequence in the
TP53 gene [35].
On the basis of our results, T:G and 5-BrU:G mis-
matches, resulting from the deamination of 5-mC:G and
5-BrC:G, respectively, markedly enhanced the mutagenic
potential compared with that of the U:G mismatch. Al-
though it has been suggested that human thymine DNA
glycosylase and methyl-CpG binding protein 4 excise thy-
mine and 5-BrU paired with guanine at CpG dinucleotides
[21, 36–38], they might play minor roles in repair in cells.
Thus, once deamination of the modified cytosine occurs,
the deaminated residues could steadily induce mutations.
Because the frequencies of C:G to T:A transition mutations
induced by 5-mC and 5-BrC were 0.44 % (4.4 × 10−3) and
0 % (<10−3), respectively (Table 1), the frequencies of de-
amination of them might be equal to or less than the order
of 10−3 in TSCER122 cells. Taking these findings together,
we emphasize that those deaminated bases contribute
to the mutagenesis and formation of mutational hot-
spots at specific loci, for example, CpG dinucleotides,
in the genome.
Conclusion
Overall, we revealed the mutagenic potential of modi-
fied/deaminated cytosine residues in the human genome.
Because T:G and 5-BrU:G mismatches can be highly
pro-mutagenic, the rate-limiting step in the formation of
mutational hotspots might be the deamination of modified
cytosine residues. Our results are also useful to further
study the mechanisms by which genomic integrity is
maintained.
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